A detailed history of Exchange Traded Concepts, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Exchange Traded Concepts, LLC holds 40,292 shares of ARWR stock, worth $805,034. This represents 0.02% of its overall portfolio holdings.

Number of Shares
40,292
Previous 48,976 17.73%
Holding current value
$805,034
Previous $1.27 Million 38.68%
% of portfolio
0.02%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$19.36 - $29.54 $168,122 - $256,525
-8,684 Reduced 17.73%
40,292 $780,000
Q2 2024

Aug 13, 2024

BUY
$21.87 - $28.24 $435,366 - $562,173
19,907 Added 68.48%
48,976 $1.27 Million
Q1 2024

Apr 15, 2024

SELL
$27.21 - $39.48 $399,524 - $579,684
-14,683 Reduced 33.56%
29,069 $831,000
Q4 2023

Jan 05, 2024

BUY
$21.2 - $31.03 $927,542 - $1.36 Million
43,752 New
43,752 $1.34 Million
Q1 2023

Apr 12, 2023

BUY
$23.68 - $38.51 $8,808 - $14,325
372 Added 0.73%
51,272 $1.3 Million
Q4 2022

Jan 17, 2023

BUY
$28.0 - $40.56 $244,272 - $353,845
8,724 Added 20.68%
50,900 $2.07 Million
Q3 2022

Oct 07, 2022

SELL
$29.63 - $48.31 $231,765 - $377,880
-7,822 Reduced 15.64%
42,176 $1.39 Million
Q2 2022

Jul 20, 2022

SELL
$27.79 - $50.61 $51,300 - $93,426
-1,846 Reduced 3.56%
49,998 $1.76 Million
Q1 2022

Apr 26, 2022

BUY
$39.62 - $69.97 $1.21 Million - $2.14 Million
30,654 Added 144.66%
51,844 $2.38 Million
Q4 2021

Jan 13, 2022

SELL
$58.09 - $82.51 $312,814 - $444,316
-5,385 Reduced 20.26%
21,190 $1.41 Million
Q3 2021

Oct 18, 2021

BUY
$58.38 - $84.96 $313,617 - $456,405
5,372 Added 25.34%
26,575 $1.66 Million
Q2 2021

Jul 30, 2021

SELL
$62.15 - $90.32 $115,909 - $168,446
-1,865 Reduced 8.08%
21,203 $1.76 Million
Q1 2021

Apr 20, 2021

BUY
$61.35 - $90.47 $1.42 Million - $2.09 Million
23,068 New
23,068 $1.53 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.11B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Exchange Traded Concepts, LLC Portfolio

Follow Exchange Traded Concepts, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exchange Traded Concepts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exchange Traded Concepts, LLC with notifications on news.